Exelixis
EXEL
#1653
Rank
C$18.75 B
Marketcap
C$75.69
Share price
-1.47%
Change (1 day)
45.40%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): C$4.31

According to Exelixis's latest financial reports the company's current EPS (TTM) is C$4.35. In 2025 the company made an earnings per share (EPS) of C$4.02.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$4.317.38%
2025C$4.02
2023C$0.9114.61%
2022C$0.79-22.97%
2021C$1.03100%
2020C$0.51-65.09%
2019C$1.47-53.91%
2018C$3.20333.96%
2017C$0.74-260.61%
2016C-$0.46-58.75%
2015C-$1.11-42.45%
2014C-$1.935.3%
2013C-$1.83

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
C$12.14 179.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
C$1.82-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
C$20.13 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
C$3.56-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
C$4.97 14.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
C$4.95 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
C$5.40 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
C-$33.08-860.38%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
C-$1.17-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA